Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. (EVGN) is a computational biology and chemistry company that regularly publishes news about its AI‑driven platforms, collaborations and corporate developments. The EVGN news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Evogene applies big data and artificial intelligence to life‑science product discovery in pharmaceuticals and agriculture.
Recent announcements highlight Evogene’s focus on ChemPass AI, its generative AI tech‑engine for small‑molecule design and optimization. News items include the completion of a generative AI foundation model for small‑molecule design developed with Google Cloud, as well as updates on how ChemPass AI is being positioned as the core engine for the company’s pharma and agricultural activities.
Evogene’s news also covers scientific collaborations, such as agreements with Unravel Biosciences to design small‑molecule therapeutics for demyelinating diseases and with a Tel Aviv University research group to develop small molecules targeting metabolite self‑assembly in metabolic diseases. In agriculture, readers can find updates related to subsidiaries like Casterra Ag, including partnerships to advance mechanized castor farming for bio‑based industries.
In addition, the EVGN news stream features financial and corporate communications, including quarterly results, conference call schedules, investor conference presentations, restructuring steps and transactions such as the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. Investors and observers can use this page to monitor how Evogene’s strategy, partnerships and technology platforms evolve over time.
Evogene Ltd. (NASDAQ: EVGN) announced its financial results for 2020, highlighting a cash position of approximately $48.2 million by year-end. The company reported a consolidated net cash usage of $19.3 million for the year, with expectations of increased usage in 2021-2022 as subsidiaries progress in product development. The operating loss for 2020 was $24.8 million, up from $21.2 million in 2019. Despite increased expenses, Evogene is optimistic about its subsidiaries' advancements, particularly in immuno-oncology and herbicides, aiming for commercialization milestones in the near future.
On February 24, 2021, Cannbit Ltd. and Canonic Ltd., both leaders in the medical cannabis sector, announced a collaboration to develop novel cannabis products. The partnership aims to leverage Cannbit's extensive clinical data and Canonic's advanced computational biology platform to address key challenges in the cannabis industry. Each company will retain full commercial rights to the products developed, with cross-royalties in place. Financial terms were not disclosed, but both companies expressed optimism about the competitive advantage this collaboration could provide.
On February 24, 2021, Cannbit, a subsidiary of Tikun Olam-Cannbit, and Canonic, a subsidiary of Evogene (NASDAQ: EVGN), announced a collaboration to develop novel medical cannabis products. This agreement aims to combine Cannbit's extensive clinical data and Canonic's computational biology platform to address challenges in the medical cannabis industry. Both companies will have full commercial rights to the products developed, with cross royalties in place. Financial details were not disclosed, but the collaboration is seen as a strategic growth opportunity for both firms.
Evogene Ltd. (NASDAQ: EVGN) announced it will release its financial results for Q4 and full-year 2020 on March 3, 2021. The company aims to revolutionize life-science product development through its Computational Predictive Biology platform, applicable in human health and agriculture. During the release, Dr. Arnon Heyman, CEO of Canonic Ltd., will discuss its activities. A conference call is scheduled at 09:00 AM ET, with access available via phone and live webcast. A replay will be accessible following the call until March 5, 2021.
Biomica Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the Crohn's & Colitis Congress® taking place virtually from January 21-24, 2021. Prof. Yehuda Ringel will present on the live bacterial consortium BMC322, developed for treating inflammatory bowel disorders (IBD), during a session on January 23 at 2 PM (EST). The study's abstract was recognized for its high quality, ranking in the top 10% of submissions.
Biomica specializes in microbiome-based therapeutics, focusing on conditions like antibiotic resistance and GI disorders.
Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), will present at the Microbiome Movement Drug Development Europe Conference on January 28-29, 2021. CEO Dr. Elran Haber will participate in a panel discussing strategies for microbiome-based therapeutics, while VP Dr. Shiri Meshner will unveil pre-clinical trial results from their immune-oncology program. The conference aims to explore market strategies and regulatory support for the microbiome sector. Biomica focuses on innovative microbiome-based therapies addressing antibiotic resistance and gastrointestinal disorders.
Evogene Ltd. (NASDAQ: EVGN) announced a year-end update for the CRISPR-IL consortium, with Dr. Eyal Emmanuel as Chairman. The consortium completed the first version of the AI-driven genome-editing platform, "Go-Genome," improving precision and efficiency. New members Better Seeds and FreeZem joined, expanding the platform's applicability. The CRISPR-CAS technology aims to develop therapeutics and agricultural products, targeting a $500 billion market by 2025. The consortium addresses challenges such as off-target edits and inefficient modifications, positioning Evogene at the forefront of CRISPR technology.
Lavie Bio, a subsidiary of Evogene (NASDAQ: EVGN), announced progress on its product pipeline for 2020, highlighting the advancement of bio-stimulant LAV211 towards a commercial launch planned for 2022. LAV211, targeting spring wheat, aims to benefit farmers by enhancing productivity, potentially delivering an additional $20 per acre. The company also detailed advancements in its bio-pesticides, specifically LAV311 and LAV312, which target bunch rot diseases and are set for launch in 2024. Lavie Bio's innovative approach utilizes its Biology Driven Design platform, enhancing its product development.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has signed its first commercial agreement with Telcann Ltd. to provide plant growth services in Israel. This agreement completes a crucial step in Canonic's medical cannabis production infrastructure, allowing them to launch their products, MetaYield and Precise, starting in 2022. The Israeli medical cannabis market is projected to grow significantly, with estimates reaching 250,000 active patients by 2025, representing a potential $220 million annual market.
AgPlenus Ltd., a subsidiary of Evogene (NASDAQ: EVGN), has successfully reached the 'Lead' stage in its Mode-of-Action herbicide program with its candidate APH1. This milestone follows positive field tests indicating APH1 effectively controls resistant weeds, achieving 70%-100% control in 6 out of 9 commercial weed species. Notably, APH1 has shown efficacy against glyphosate-resistant strains and demonstrated crop selectivity. The development of this novel herbicide addresses critical herbicide resistance issues, with the global market for herbicides projected to hit $34 billion by 2022.